If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
165
results.
Updated on
14/07/2025 [06:56:00]
Results 50 to 75 of 165
Absstract of: US2025197515A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Absstract of: WO2025127611A1
According to one embodiment, a wearable electronic device comprises a first sensor, at least one second sensor, a memory, a display, a communication circuit and at least one processor, wherein the memory can store instructions that, when executed by the at least one processor, cause the wearable electronic device to: identify, on the basis of a first sensing value identified through the at least one second sensor, a first time point so as to measure first blood glucose data of a user wearing the wearable electronic device; use an external device at the first time point so as to display, through the display, first guide information for allowing the blood glucose of the user to be measured; measure, through the first sensor, a second sensing value indicating a first biometric signal of the user at the first time point; acquire, through the communication circuit, information indicating a first blood glucose value of the user measured at the first time point by the external device; and acquire, on the basis of the first blood glucose value and a second sensing value indicating the first biometric signal, calibration data for determining a blood glucose value of the user on the basis of sensing values indicating biometric signals of the user to be measured using the first sensor.
Absstract of: US2025195761A1
Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e.g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Absstract of: EP4552558A2
The present disclosure relates to a body attachment unit for continuous blood glucose measurement, in which the body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without performing additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start point in time can be adjusted to an appropriate point in time according to the user's needs, and activation occurs in a stabilized state, thereby providing the body attachment unit allowing more accurate blood glucose measurement.
Absstract of: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Absstract of: WO2025127627A1
The present invention relates to an exercise management method and system for managing blood sugar variability. The method according to the present invention comprises the steps of: obtaining data on the timing of postprandial blood sugar spikes on the basis of a user's blood sugar data acquired during a first period; calculating an optimal start time for postprandial aerobic exercise on the basis of the data on the timing of postprandial blood sugar spikes; and providing an alert for the start time of postprandial aerobic exercise on the basis of the optimal start time for postprandial aerobic exercise during a second period. According to the present invention, it is possible to recommend an effective postprandial aerobic exercise time tailored to a user's blood sugar pattern. In addition, it is possible to prompt a user to start aerobic exercise at the optimal time point for postprandial aerobic exercise according to the meal. Furthermore, by analyzing and providing the improvement in blood sugar levels of postprandial aerobic exercise, the user's will to perform postprandial aerobic exercise can be encouraged and adherence to exercise can be enhanced.
Absstract of: US2025195781A1
Disclosed are systems and methods for a computerized framework that electronically manages and controls a patient's therapy for proper administration of diabetic treatment. The framework includes a disposable pen injector that has integrated therein dose logging capabilities (e.g., a NFC circuit) for controlling the administration of the prescribed therapy. Electronic communications between the disposable pen injector and a therapy control application executing on a patient's device can effectuate accurate and efficient administration of prescribed therapy. The pen can communicate information to the patient's device, and the application executing thereon, that includes dosage information related to availability left in the pen, timing of doses, and the like. In a related manner, the application can compile dosage planning information that can dictate types of doses, amounts of doses, timing of doses, and the like, to ensure that the patient is complying with a prescribed diabetic prescription.
Absstract of: AU2025203882A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Absstract of: AU2025203909A1
A controller in an insulin delivery system for the delivery of insulin to a patient, the controller configured to control operation of an insulin delivery device, the controller comprising: a chipset for establishing communications with a glucose monitor and a smartphone; one or more processors; and computer memory storing instructions that, when executed by the one or more processors, cause the one or more processors to: establish, using the chipset, a first network connection with the glucose monitor; establish, using the chipset, a second network connection with the smartphone, the smartphone running a mobile application, wherein the mobile application is executed by the smartphone; receive, via the first network connection, patient data related to blood glucose levels from the glucose monitor; transmit, via the second network connection, the patient data related to blood glucose levels to the smartphone; and receive, from the smartphone via the second network connection, an instruction to administer an insulin dosage, wherein the instruction to administer the insulin dosage is initiated by the mobile application running on the smartphone, and wherein the insulin dosage is based at least in part on the patient data related to blood glucose levels transmitted to the smartphone; and transmit, to the smartphone via the second network connection, a communication verifying that the administration of the insulin dosage has been completed.
Absstract of: US2025194970A1
The present invention provides a diabetes biosensor including a porous polymer membrane; two sides of the porous polymer membrane are provided with impermeable membranes; the impermeable membrane on one side is provided with a first electrode, the impermeable membrane on the other side is provided with a second electrode. Specific glucose oxidase is immobilized on the first electrode. In the present invention, the porous polymer membrane has the feature of multiple pores to facilitate the penetration of water and other liquids, and the impermeable membranes on two sides of the porous polymer membrane have the feature of impermeable; the porous polymer membrane, the impermeable membranes, the first electrode, and the second electrode together constitute a sandwich sensor; glucose generates hydrogen peroxide under the action of glucose oxidase; after the hydrogen peroxide generates electron gain and loss on the electrode, an electric signal change is generated and detected by the biosensor; and the biosensor can rapidly measure the blood glucose concentration. In addition, the biosensor can be used as a device for storing drugs, which facilitates the use of the biosensor to inject insulin into a patient with a high blood glucose concentration to control the blood glucose level.
Absstract of: US2025195196A1
The development of devices for a functional cure for diabetes by mimicking native pancreatic tissue for production of all pancreatic hormones. A physiologically and mechanically biocompatible artificial pancreas, wherein the pancreas comprises a combination of a PVA hydrogel combined with cells selected from the group consisting of islets; clusters of islets; Beta cells, and combinations of islets and Beta cells. The bioartificial pancreas contains vascular grafts therein or thereon a wall of the pancreas so that said grafts are an integral part of the wall of the bioartificial pancreas. The grafts can be anasmotized to living blood vessels in the body.
Absstract of: US2025195000A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Absstract of: US2025194964A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Absstract of: US2025195002A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: US2025195755A1
A device for delivering medicament to a user is disclosed. The device is configured to be mounted to the user. The device comprises a baseplate including: an inlet opening and outlet opening to align with an inlet opening and outlet opening of a micropump, respectively; a first port for fluid in fluid communication with a catheter; and a first fluid channel to enable fluid communication between the first port and the outlet opening of the micropump; and a housing configured to engage the baseplate to form an interior therein, the interior including a first internal region that is sealed from fluid ingress and a second internal region that is not sealed from fluid ingress, wherein the inlet opening of the baseplate, the outlet opening of the baseplate and the first port are within the first internal region.
Absstract of: US2025195753A1
A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.
Absstract of: US2025152053A1
A glucose measurement device comprising a light emitting device comprising an SWIR phosphor having emission wavelengths in the range of 1600-2200 nm, the SWIR phosphor comprising a structurally disordered garnet material, a sensitizer ion, and at least one rare earth emitter ion, and a infrared light detector arranged to detect the intensity of short wavelength infrared light emitted by the light emitting device and reflected by a sample. The emission spectra provided by the light emitting device having a high temperature stability at infrared absorption minima and maxima wavelengths of glucose in tissue.
Absstract of: EP4570286A1
This invention discloses a protective mechanism for insulin needles and an insulin injection device. Through the cooperation of a U-shaped reciprocating slot and a flexible wall, it is possible to automatically retract the needle tip after injection, and prevent it from being pushed out again, thus achieving the purpose of needle tip protection and avoiding reuse.
Absstract of: US2025185949A1
The present invention discloses a state-of-the-art non-invasive blood glucose monitoring system powered by radio frequency (RF) signals to determine glucose levels in the blood. The system consists of a sensor plate, which functions as an antenna, transmitting RF signals through the body and analyzing the reflection coefficient to detect changes in blood glucose concentration. A Voltage Standing Wave Ratio (VSWR) meter is integrated with the device to measure the reflection of the RF signal, which is indicative of the body's impedance mismatch due to glucose variations. The system incorporates a microcontroller, which processes the forward and reverse voltage signals obtained from the VSWR meter to calculate the reflection coefficient. In addition, a Bluetooth system is included for wireless data transmission to a secondary device, such as a smartphone or PC, where a specialized software application processes the VSWR data to estimate the blood glucose level through quadratic interpolation. The efficacy of the system is validated against standard glucometer readings, demonstrating its potential as a convenient and pain-free alternative for diabetes management and monitoring. The device's architecture and its components are designed to ensure user-friendly operation, precise measurements, and seamless integration into the user's lifestyle.
Absstract of: US2025191743A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Absstract of: WO2025122639A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Absstract of: US2025185951A1
In response to insertion of a continuous glucose monitoring (CGM) sensor into the skin of user, a CGM system compares an identifier of the sensor to any previously-stored identifiers of previously-inserted sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier and a time stamp are stored and CGM may begin. Upon removal of the sensor, a removal time stamp is stored. If the identifier of an inserted sensor matches a previously-stored identifier, indicating a reinserted sensor, a reinsertion time is obtained and an elapsed removal time is checked to determine whether it exceeds a maximum removal time limit. If it does, CGM is halted. If it does not, CGM may continue with the reinserted sensor. Methods of tracking insertion and removal times of a CGM sensor are also provided, as are other aspects.
Absstract of: US2025185950A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Absstract of: US2025186696A1
Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other remote consumer electronic device and/or a dedicated remote controller for the infusion pump. In order to ensure reliable communication of data, more than one component in a system can be capable of relaying data to another component.
Nº publicación: US2025186695A1 12/06/2025
Applicant:
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
Absstract of: US2025186695A1
The subject matter of this disclosure generally relates to a medical device system and related methodologies that leverage data associated with the use of a meal transaction application, such as an application for ordering food delivery. Data generated by the meal transaction application can be leveraged by a patient care system or application for purposes of diet or calorie logging. Alternatively or additionally, the meal transaction data can be leveraged for purposes of controlling the administration of therapy by a medication delivery system, such as an insulin infusion pump.
BOPI
Electronic site
